TELA Bio shares jump 11.38% intraday after appointing William Plovanic to its board.

TELA Bio surged 11.38% during intraday trading following the announcement that William Plovanic, a seasoned capital markets and medical technology leader, joined its board of directors. The appointment, disclosed on November 3, 2025, highlighted Plovanic’s expertise as a former CEO and CFA, emphasizing his ability to enhance corporate strategy and shareholder value. This move reinforced investor confidence in TELA Bio’s governance and long-term growth prospects. While the company also announced Q3 2025 earnings results on November 13, the immediate price reaction aligned with the board appointment, which directly signaled strategic and operational credibility. The earnings disclosure, being a scheduled event without preliminary data, lacked the immediacy to drive such a sharp intraday rally.